June 8, 2020
Authored and Edited by Kathryn R. Judson; Thomas L. Irving
On May 27, 2020, FDA issued draft guidance on questions and answers related to the Orange Book. FDA intends the guidance to assist drug product applicants and other interested parties in utilizing the Orange Book.
The questions for which FDA provides answers relate to (1) the content and format of the Orange Book, (2) petitioned ANDAs, (3) moving drug products between the active and discontinued sections of the Orange Book, and (4) patent listings.
For example, FDA explains that newly approved NDA drug products will generally appear in the active section of the Orange Book in the month following their approval and generally remain thereafter. However, if the NDA holder notifies FDA that the drug product will not be available for sale within 180 days of approval, then the NDA drug product will, in the month following such approval, appear in the discontinued section of the Orange Book. In addition, FDA explains that a person other than an NDA holder can dispute the accuracy or relevance of patent information published in the Orange Book by submitting a narrative statement of dispute to FDA in a written or electronic communication describing the specific grounds for disagreement. FDA will then forward the statement to the applicable NDA holder without review or redaction.
Readers are encouraged to read the draft guidance, also available on FDA’s website.
Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.